Strauss Troy Co. has filed a civil lawsuit in federal court in the Southern District of Ohio against Bayer, manufacturer of the drug Xarelto®, and Janssen Pharmacefuticals (a subsidiary of Johnson & Johnson that marketed the drug in the U.S.).
Xarelto (generic name rivaroxaban) is generally referred to as a blood thinner. It is prescribed by physicians to reduce the risk of stroke, to treat pulmonary embolism and to prevent deep vein thrombosis (DVT) in persons who have had joint replacement surgery.
The Complaint alleges that the Plaintiff suffered internal bleeding in her knee and calf after taking Xarelto following a total knee replacement. “During a prior knee replacement, she was prescribed Heparin and had no such adverse effects,” said Strauss Troy Attorney Ron Parry.
The Complaint also alleges that, unlike other blood thinners, there is no antidote to Xarelto. Therefore, in the event of hemorrhagic complications, there is no available reversal agent. The original U.S. label approved when the drug was first marketed in the U.S. did not contain a warning regarding the lack of antidote, but instead only mentioned this important fact in the over dosage section.
Xarelto has been heavily promoted by Johnson and Johnson, including a frequently seen TV commercial featuring Arnold Palmer. There is some indication that Arnold Palmer’s use of Xarelto may have been a contributing factor in his death.
The lawsuit filed by Strauss Troy is one of over 10,000 lawsuits filed throughout the country relating to Xarelto. The Judicial Panel on Multidistrict Litigation has consolidated all of the cases in the Eastern District of Louisiana for pretrial proceedings.
If you or a family member has suffered similar damages or injuries due to Xarelto, you can contact Strauss Troy for a case evaluation and to learn more about your legal rights.
Contact:
Attorney Ron Parry
rrparry@strausstroy.com
513-629-9485